BioMarin Pharmaceutical BMRN reported first-quarter 2026 adjusted earnings per share of 76 cents, missing the Zacks Consensus Estimate of 94 cents. However, earnings declined 33% year over year. This was largely due to a $31 million charge tied to the company’s unsuccessful campaign to extend Naglazyme manufacturing capabilities,

Vertex, BioMarin, and IQVIA reported Q1 2026 results showing revenue growth but varied earnings outcomes. Vertex posted 8% revenue growth to $2.99 billion, BioMarin saw a 3% revenue rise but missed EPS estimates, and IQVIA beat forecasts with 8.4% revenue ...

Shortly after taking the reins at BioMarin, CEO Alexander Hardy laid out three paths the company could take for its struggling hemophilia A gene therapy, Roctavian. A year after opting to shrink the drug’s commercial reach, BioMarin has now flipped back ...

VOXZOGO is the only approved treatment for children with achondroplasia starting at birth, with over 10 years of clinical research demonstrating the long-term benefit on complications associated with

BioMarin Pharmaceutical's (NASDAQ: BMRN) website doesn't show any scheduled events on its calendar over the next month. However, that means nothing. The drugmaker will almost certainly report its 2025 full-year and fourth-quarter results in the coming weeks.

BioMarin Pharmaceutical made a slew of executive hires to bolster its R&D and business development leadership on Wednesday. Most notably, the company hired James Sabry as EVP, chief business officer. Sabry joins BioMarin from Roche, where he most recently ...

VOXZOGO contribution to full-year 2025 Total Revenues expected to be in the range of $900 million to $950 million. Refer to Non-GAAP Information beginning on page 10 of this press release for definitions of Non-GAAP Operating Margin and Non-GAAP Diluted EPS.

BioMarin has a near $3bn per annum rare disease drug franchise, and is profitable. Arguably the business is undervalued by the market. The company faces threats to key drugs in the indications of achondroplasia, hemophilia and patent expiry issues, making ...